IN2014MN02661A - - Google Patents
Info
- Publication number
- IN2014MN02661A IN2014MN02661A IN2661MUN2014A IN2014MN02661A IN 2014MN02661 A IN2014MN02661 A IN 2014MN02661A IN 2661MUN2014 A IN2661MUN2014 A IN 2661MUN2014A IN 2014MN02661 A IN2014MN02661 A IN 2014MN02661A
- Authority
- IN
- India
- Prior art keywords
- ampk
- treatment
- activators
- liver disease
- non alcoholic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Activators of AMPK and therapeutic uses thereof The invention relates to compounds that are direct activators of AMPK (AMP activated protein kinase) and their use in the treatment of disorders regulated by activation of AMPK. For instance compounds according to the invention are useful for the treatment of diabetes metabolic syndrome obesity liver disease hepatic steatosis non alcoholic fatty liver disease (NAFLD) non alcoholic steato hepatitis (NASH) liver fibrosis dyslipidemia hypertriglyceridemia hypercholesterolemia inflammation cancer cardiovascular diseases atherosclerosis high blood pressure retinopathies or neuropathies.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305775.4A EP2679591A1 (en) | 2012-06-29 | 2012-06-29 | Thienopyridone derivatives useful as activators of AMPK |
| PCT/EP2013/063741 WO2014001554A1 (en) | 2012-06-29 | 2013-06-28 | Thienopyridone derivatives useful as activators of ampk |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02661A true IN2014MN02661A (en) | 2015-08-28 |
Family
ID=48703549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2661MUN2014 IN2014MN02661A (en) | 2012-06-29 | 2013-06-28 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9284329B2 (en) |
| EP (2) | EP2679591A1 (en) |
| JP (1) | JP5972460B2 (en) |
| KR (1) | KR101704448B1 (en) |
| CN (2) | CN104395319B (en) |
| AU (1) | AU2013283239B2 (en) |
| BR (1) | BR112014032526B1 (en) |
| CA (1) | CA2876789C (en) |
| CY (1) | CY1118213T1 (en) |
| DK (1) | DK2867240T3 (en) |
| EA (1) | EA026300B1 (en) |
| ES (1) | ES2603737T3 (en) |
| HR (1) | HRP20161482T1 (en) |
| HU (1) | HUE030946T2 (en) |
| IL (1) | IL236221A (en) |
| IN (1) | IN2014MN02661A (en) |
| LT (1) | LT2867240T (en) |
| ME (1) | ME02537B (en) |
| MX (1) | MX359221B (en) |
| PL (1) | PL2867240T3 (en) |
| PT (1) | PT2867240T (en) |
| RS (1) | RS55308B1 (en) |
| SI (1) | SI2867240T1 (en) |
| SM (1) | SMT201600418B (en) |
| WO (1) | WO2014001554A1 (en) |
| ZA (1) | ZA201500593B (en) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105078992B (en) * | 2014-05-23 | 2017-11-21 | 资元堂生物科技股份有限公司 | Isoquinoline alkaloids alkali derivant is used for the purposes for preparing the medicine for promoting AMPK activity |
| CN104945370A (en) * | 2015-06-23 | 2015-09-30 | 佛山市赛维斯医药科技有限公司 | Xanthate compound containing halothiophene and nitrobenzene hexamethylbenzene structure, preparation method and application |
| CN104892568A (en) * | 2015-06-23 | 2015-09-09 | 佛山市赛维斯医药科技有限公司 | Xanthate ester compound containing haxamethyl benzene ring and nitrile group benzene structure and preparation method and application of xanthate ester compound |
| CN104910129A (en) * | 2015-06-23 | 2015-09-16 | 佛山市赛维斯医药科技有限公司 | Xanthate compounds containing hexamethyl benzene ring and halogeno-benzene, and preparation method and application thereof |
| CN104910130A (en) * | 2015-06-23 | 2015-09-16 | 佛山市赛维斯医药科技有限公司 | Xanthate compound containing hexamethylbenzene ring and aminobenzene structures as well as preparation method and application thereof |
| CN104892569A (en) * | 2015-06-23 | 2015-09-09 | 佛山市赛维斯医药科技有限公司 | Terminal-substituted nitrobenzene hexamethylbenzene xanthate compound, preparation method and application |
| CN104945369A (en) * | 2015-06-23 | 2015-09-30 | 佛山市赛维斯医药科技有限公司 | Xanthic acid ester compound containing hexamethyl benzene ring and nitrobenzene structures and preparation method and application thereof |
| CN105037321A (en) * | 2015-06-23 | 2015-11-11 | 佛山市赛维斯医药科技有限公司 | Xanthate AMPK activating agents comprising hexamethylbenzene ring structures, as well as preparation methods and application thereof |
| CN105001181A (en) * | 2015-06-24 | 2015-10-28 | 佛山市赛维斯医药科技有限公司 | Bisacyl benzylamine AMPK activator, and preparation method and application thereof |
| CN105037296A (en) * | 2015-06-24 | 2015-11-11 | 佛山市赛维斯医药科技有限公司 | AMPK activator containing halogenated-benzene bisamides benzylamine structures, and preparation method and application thereof |
| CN104945372A (en) * | 2015-06-24 | 2015-09-30 | 佛山市赛维斯医药科技有限公司 | Dinitrosalicylic xanthate ester compound with hexamethylbenzene structure and preparation method and application thereof |
| CN104926756A (en) * | 2015-06-24 | 2015-09-23 | 佛山市赛维斯医药科技有限公司 | Di-acyl benzylamine compound with cyano benzene, method for manufacturing di-acyl benzylamine compound and application thereof |
| CN104926757A (en) * | 2015-06-24 | 2015-09-23 | 佛山市赛维斯医药科技有限公司 | Diacyl benzylamine AMPK activator containing alcoxyl phenyl group, and preparation method and purpose of diacyl benzylamine AMPK activator |
| CN104926755A (en) * | 2015-06-24 | 2015-09-23 | 佛山市赛维斯医药科技有限公司 | Nitrobenzene di-acyl benzylamine AMPK (adenosine monophosphate activated protein kinase) activator, method for manufacturing same and application of nitrobenzene di-acyl benzylamine AMPK activator |
| CN104945371A (en) * | 2015-06-24 | 2015-09-30 | 佛山市赛维斯医药科技有限公司 | Xanthate ester compound containing nitrile thiophene and with hexamethylbenzene structure and preparation method and application thereof |
| CN105541715B (en) * | 2016-02-02 | 2019-04-09 | 浙江工业大学 | (2H) the -one derivative of polysubstituted pyridine -1 and its synthetic method and application |
| KR101925020B1 (en) | 2017-04-21 | 2018-12-04 | 연세대학교 산학협력단 | Pharmaceutical composition for metabolic disease comprising expression or activity inhibitor of MKRN1 as an active ingredient |
| SG11202006723SA (en) * | 2018-02-08 | 2020-08-28 | Enyo Pharma | Non-fused thiophene derivatives and their uses |
| CN108516972A (en) * | 2018-05-30 | 2018-09-11 | 王丽萍 | A kind of GOAT inhibitor and its application in fat and diabetes |
| MX2021005772A (en) * | 2018-11-16 | 2021-10-13 | Poxel | Monohydrate potassium salt of a thienopyridone derivative and its preparation process. |
| US20220184172A1 (en) * | 2019-04-19 | 2022-06-16 | The Regents Of The University Of California | Ampk/caspase-6 axis controls liver damage in nonalcoholic steatohepatitis |
| WO2021037702A1 (en) | 2019-08-28 | 2021-03-04 | Poxel | Pharmaceutical combination of a specific thienopyridone derivative with an fxr agonist for the treatment of liver diseases |
| WO2021105075A1 (en) * | 2019-11-27 | 2021-06-03 | Société des Produits Nestlé S.A. | Dibenzopyran ampk activator compounds, compositions, methods and uses thereof |
| EP4125886A1 (en) | 2020-03-26 | 2023-02-08 | Poxel | Use of a thienopyridone derivative in the treatment of adrenoleukodystrophy or adrenomyeloneuropathy |
| WO2021198284A1 (en) | 2020-03-30 | 2021-10-07 | Poxel | Use of a thienopyridone derivative in the treatment of cardiovascular diseases |
| US20230149370A1 (en) | 2020-03-30 | 2023-05-18 | Poxel | Use of a thienopyridone derivative in the treatment of diabetic nephropathy |
| DK4125887T3 (en) * | 2020-04-02 | 2024-05-06 | Poxel | USE OF A THIENOPYRIDONE DERIVATIVE IN THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) |
| WO2021204755A1 (en) | 2020-04-06 | 2021-10-14 | Poxel | Pharmaceutical combination for the treatment of liver diseases |
| WO2021204751A1 (en) | 2020-04-06 | 2021-10-14 | Poxel | Pharmaceutical combination for the treatment of liver diseases |
| UY39222A (en) | 2020-05-19 | 2021-11-30 | Kallyope Inc | AMPK ACTIVATORS |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
| CN116322663A (en) | 2020-09-30 | 2023-06-23 | 比奥维拉迪维治疗股份有限公司 | AMPK activators and methods of use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4444815A1 (en) * | 1994-12-15 | 1996-06-20 | Merck Patent Gmbh | Thienopyridone |
| US7119205B2 (en) | 2003-05-16 | 2006-10-10 | Abbott Laboratories | Thienopyridones as AMPK activators for the treatment of diabetes and obesity |
| US7407966B2 (en) * | 2004-10-07 | 2008-08-05 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
| EP1754483A1 (en) * | 2005-08-18 | 2007-02-21 | Merck Sante | Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them |
| DK2262500T3 (en) | 2008-04-11 | 2016-08-15 | Merck Patent Gmbh | THIENOPYRIDON DERIVATIVES AS AMP-ACTIVATED PROTEINKINASE (AMPK) ACTIVATORS |
| MY160357A (en) * | 2008-05-05 | 2017-02-28 | Merck Patent Gmbh | Thienopyridone derivatives as amp-activated protein kinase (ampk) activators |
-
2012
- 2012-06-29 EP EP12305775.4A patent/EP2679591A1/en not_active Ceased
-
2013
- 2013-06-28 AU AU2013283239A patent/AU2013283239B2/en active Active
- 2013-06-28 WO PCT/EP2013/063741 patent/WO2014001554A1/en active Application Filing
- 2013-06-28 PT PT137325338T patent/PT2867240T/en unknown
- 2013-06-28 PL PL13732533T patent/PL2867240T3/en unknown
- 2013-06-28 EA EA201500064A patent/EA026300B1/en not_active IP Right Cessation
- 2013-06-28 US US14/411,690 patent/US9284329B2/en active Active
- 2013-06-28 CN CN201380034638.0A patent/CN104395319B/en active Active
- 2013-06-28 HU HUE13732533A patent/HUE030946T2/en unknown
- 2013-06-28 MX MX2014016107A patent/MX359221B/en active IP Right Grant
- 2013-06-28 IN IN2661MUN2014 patent/IN2014MN02661A/en unknown
- 2013-06-28 BR BR112014032526-0A patent/BR112014032526B1/en active IP Right Grant
- 2013-06-28 CA CA2876789A patent/CA2876789C/en active Active
- 2013-06-28 EP EP13732533.8A patent/EP2867240B1/en active Active
- 2013-06-28 RS RS20160977A patent/RS55308B1/en unknown
- 2013-06-28 ES ES13732533.8T patent/ES2603737T3/en active Active
- 2013-06-28 LT LTEP13732533.8T patent/LT2867240T/en unknown
- 2013-06-28 JP JP2015519153A patent/JP5972460B2/en active Active
- 2013-06-28 CN CN201710493350.XA patent/CN107266467A/en active Pending
- 2013-06-28 SI SI201330379A patent/SI2867240T1/en unknown
- 2013-06-28 DK DK13732533.8T patent/DK2867240T3/en active
- 2013-06-28 KR KR1020157002599A patent/KR101704448B1/en active IP Right Grant
- 2013-06-28 ME MEP-2016-240A patent/ME02537B/en unknown
-
2014
- 2014-12-11 IL IL236221A patent/IL236221A/en active IP Right Grant
-
2015
- 2015-01-27 ZA ZA2015/00593A patent/ZA201500593B/en unknown
-
2016
- 2016-11-09 CY CY20161101141T patent/CY1118213T1/en unknown
- 2016-11-09 HR HRP20161482TT patent/HRP20161482T1/en unknown
- 2016-11-17 SM SM201600418T patent/SMT201600418B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN02661A (en) | ||
| MX2018005193A (en) | Dual function proteins and pharmaceutical composition comprising same. | |
| EP3212221A4 (en) | Efficient delivery of therapeutic molecules in vitro and in vivo | |
| EP3204032A4 (en) | Efficient delivery of therapeutic molecules in vitro and in vivo | |
| PH12015500407A1 (en) | Methods of treating hypertriglyceridemia | |
| EA201391737A1 (en) | NEW CONNECTIONS AS DIACYLGLYCEROLACILTRANSFERASE INHIBITORS | |
| IN2014MN00986A (en) | ||
| IN2012MN02591A (en) | ||
| IL231536A (en) | Indazole-3-carboxamides , pharmaceutical compositions comprising them and their use in the treatment of diseases | |
| DK3444261T3 (en) | 2,2-DIFLUOROPROPIONAMIDE DERIVATIVE OF BARDOXOLONE METHYL, PHARMACEUTICAL COMPOSITIONS AND POLYMORPHES THEREOF FOR USE IN THE TREATMENT OF CERTAIN DISORDERS | |
| IN2012DN06720A (en) | ||
| HK1199220A1 (en) | Pharmaceutical composition for the prevention or treatment of non- alcoholic fatty liver disease | |
| IN2015DN00376A (en) | ||
| BR112014006220A2 (en) | galacto-ramnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic liver fat disease | |
| EE201300007A (en) | Combined pharmaceutical composition for the treatment of diabetes and metabolic disorders | |
| ZA201200944B (en) | Pharmaceutical compositions for the treatment of cancer and other diseases or disorders | |
| PH12015502108A1 (en) | Pharmaceutical combination drug | |
| AU2012334804A8 (en) | Modulators of C3a receptors | |
| IL238411A0 (en) | Herbal composition for the prevention and treatment of tnf-α mediated diseases | |
| UA115307C2 (en) | APPLICATION OF MEDICINAL PRODUCT CONTAINING RECOMBINANT LECTIN MELINES FOR TREATMENT OF SKIN CANCER | |
| UA112981C2 (en) | OPTION OF HUMAN GDNF | |
| EP2902024A4 (en) | Synergic composition of nitazoxanide and mebendazole, methods for the preparation thereof, and use of said composition for the treatment of human parasitosis | |
| PH12016501553A1 (en) | Metadoxine for use in the treatment of liver diseases, and metadoxine extended release formulations | |
| IN2013DN10341A (en) | ||
| TN2013000185A1 (en) | Inhibitors of apoptosis and uses thereof |